Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Pricing Policies Needed To Curb AMR Impact, States Industry Alliance Report

Medicines For Europe Echoes Report Recommendations

Executive Summary

The AMR Industry Alliance has put forward six different policy proposals which it says could minimize the global impact of antimicrobial resistance.

You may also be interested in...



AMR Alliance Follows Up Global Industry Standard With Responsible Manufacturing Certification

A new voluntary certification from the AMR Industry Alliance and the British Standards Institution will assess pharmaceutical firms’ responsibility and sustainability when it comes to manufacturing antibiotic drugs, in an attempt to control the spread of antimicrobial resistance.

AMR Alliance Follows Up Global Industry Standard With Responsible Manufacturing Certification

A new voluntary certification from the AMR Industry Alliance and the British Standards Institution will assess pharmaceutical firms’ responsibility and sustainability when it comes to manufacturing antibiotic drugs, in an attempt to control the spread of antimicrobial resistance.

G20 Meets Fresh Wave Of COVID With ‘Be Prepared’ Motto, Digital Focus

As the COVID-19 graph trends upward in countries like India, preparing for future pandemics is high on the agenda of intergovernmental forum G20. Digital healthcare and governance tools, One Health approach and tackling AMR emerged as focus areas at the recent meeting of its Health Working Group

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel